Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) saw unusually-high trading volume on Tuesday . Approximately 653,026 shares changed hands during trading, an increase of 22% from the previous session’s volume of 536,895 shares.The stock last traded at $70.05 and had previously closed at $68.10.

Several equities analysts have recently weighed in on the company. Jefferies Group set a $109.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 1st. Credit Suisse Group AG restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 12th. Canaccord Genuity restated a “buy” rating and issued a $120.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 16th. Wedbush restated an “outperform” rating and issued a $92.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, June 28th. Finally, Bank of America Corp. assumed coverage on Ultragenyx Pharmaceutical in a research report on Tuesday, June 28th. They issued a “buy” rating and a $72.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Ultragenyx Pharmaceutical has an average rating of “Buy” and an average price target of $99.10.

The stock has a 50 day moving average of $59.64 and a 200-day moving average of $61.80. The firm’s market capitalization is $2.74 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same period in the prior year, the firm earned ($0.83) earnings per share. Equities analysts expect that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current year.

In other news, insider Sunil Agarwal sold 650 shares of the company’s stock in a transaction on Monday, June 20th. The stock was sold at an average price of $54.16, for a total transaction of $35,204.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $67.61, for a total value of $1,352,200.00. Following the sale, the chief executive officer now owns 493,244 shares of the company’s stock, valued at $33,348,226.84. The disclosure for this sale can be found here.

Several hedge funds have recently added to or reduced their stakes in RARE. Jennison Associates LLC increased its stake in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock worth $84,739,000 after buying an additional 109,724 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in Ultragenyx Pharmaceutical by 8.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 153,788 shares of the biopharmaceutical company’s stock worth $17,252,000 after buying an additional 11,497 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock worth $6,414,000 after buying an additional 5,139 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $1,010,000.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.